MED Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medifast, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$12.63 |
| 52주 최고가 | US$15.46 |
| 52주 최저가 | US$9.22 |
| 베타 | 0.57 |
| 1개월 변동 | 14.30% |
| 3개월 변동 | 18.81% |
| 1년 변동 | -6.10% |
| 3년 변동 | -84.74% |
| 5년 변동 | -96.18% |
| IPO 이후 변동 | 129.64% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Seeking Alpha • May 12
Medifast: Worth Putting On A Watchlist
Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking Alpha내러티브 업데이트 • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.Recent updates
내러티브 업데이트 • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Seeking Alpha • May 12
Medifast: Worth Putting On A Watchlist
Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking Alpha내러티브 업데이트 • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.내러티브 업데이트 • Apr 18
MED: Metabolic Health Initiatives And Insurance Access Will Support Balanced Long-Term Outlook
Analyst price targets for Medifast have been reset, with updated assumptions pointing to a fair value of $12.00 per share. This is now based on a slightly higher discount rate, a similar revenue outlook, a higher profit margin and a lower forward P/E, which analysts cite as the main drivers of the change.내러티브 업데이트 • Apr 04
MED: Future Leadership And Metabolic Health Expansion Will Support Long-Term Upside
Analysts have marginally adjusted their price target on Medifast, reflecting slightly higher assumed profit margins and a modestly higher discount rate while keeping fair value at $12. They are framing this as a fine tuning of expectations rather than a major shift in outlook.내러티브 업데이트 • Mar 20
MED: Future Leadership Shift Will Seek To Unlock Metabolic Health Opportunity
Analysts have slightly revised their price target on Medifast, with the updated fair value holding at $12.00 as small adjustments to the discount rate and future P/E assumptions refine the underlying model rather than indicate a major change in outlook. What's in the News OPTAVIA’s comprehensive metabolic health system is now eligible for reimbursement on select insurance plans via HSA and FSA funds, which can allow some clients to use pre tax dollars toward program costs (Product related announcement).내러티브 업데이트 • Mar 05
MED: Future Leadership Shift Will Align With New Metabolic Health System
Analysts have modestly reduced their price target on Medifast, citing a slightly lower discount rate, a small improvement in projected profit margin, and a shift to a lower future P/E assumption. Together, these factors point to a more cautious valuation framework in dollar terms.내러티브 업데이트 • Feb 19
MED: Future Leadership Shift Will Present Long Term Opportunity
Analysts have trimmed their price target for Medifast from $15 to $12, citing updated assumptions that point to softer revenue growth, lower profit margins, and a higher future P/E multiple. What's in the News Medifast issued earnings guidance for the first quarter of 2026, projecting revenue between US$65,000,000 and US$80,000,000 and a loss per share in a range of US$0.15 to US$0.70 (company guidance).분석 기사 • Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) may be sending bullish signals at the...분석 기사 • May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target
It's been a good week for Medifast, Inc. ( NYSE:MED ) shareholders, because the company has just released its latest...Seeking Alpha • Jan 20
Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround
Summary Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a strategy for Medifast to acquire customers who are taking GLP-1s, starting with a collaboration with LifeMD. With a strong balance sheet, but without enough conviction of the success of their strategy, I rate Medifast a Hold. Read the full article on Seeking Alpha분석 기사 • Jan 09
An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued
Key Insights Medifast's estimated fair value is US$26.41 based on 2 Stage Free Cash Flow to Equity Medifast's US$15.64...분석 기사 • Dec 11
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) is a stock worth checking...
새로운 내러티브 • Nov 10
GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline
The adoption of weight loss medications impacts Medifast's business model, threatening future revenue and customer acquisition.Seeking Alpha • Nov 06
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Summary Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share. Risks include declining coach numbers, competition from GLP-1 medications, and short-selling pressures, but MED's current valuation appears undervalued. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Summary Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are likely to enhance FCF margins. Despite recent lower-than-expected EPS, MED's long-term financial growth and undervaluation suggest strong future stock price potential. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Medifast Business Continues To Shrink, Stock Still Risky
Summary Medifast's stock has plummeted, with dividends still suspended and earnings and revenue are in rapid decline. Despite a strong balance sheet, Medifast faces increased competition and market volatility, leading to a shrinking business. Revenue and earnings are expected to continue declining, making the stock less attractive with higher P/E ratios. Medifast's cash generation has diminished, and the company is focusing on growth rather than dividends, making it a risky investment. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Summary Medifast is a leader in dietary weight management that fell off a cliff since 2022 due to inflationary pressures, the re-opening of restaurants, and the rise of GLP-1 drugs. The company's turnaround plan aims to combine OPTAVIA offerings with direct access to GLP-1 medication through a partnership with LifeMD. At about $20 per share, Medifast may be in deep value territory, but strong negative momentum and the lack of turnaround proof points make it a HOLD at this time. Investors who seek long exposure with an increased margin of safety could consider selling $12.50 MED puts, noting that the company holds over $14 of net cash per share. Read the full article on Seeking AlphaSeeking Alpha • May 24
Medifast: Significant Undervaluation Even As Struggles Persist
Summary Medifast's financial performance is deteriorating rapidly due to the emergence of drug-weight loss competitors. The company reported a significant decline in revenue and earnings in Q1 2023. Medifast is laying off employees and may need to further reduce its workforce to match the revenue drop. My valuation analysis suggests that the stock is significantly undervalued, but I consider this fair given all the challenges. Read the full article on Seeking Alpha분석 기사 • May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Medifast, Inc. ( NYSE:MED ), might not be a large cap stock, but it received a lot of attention from a substantial...분석 기사 • May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
To the annoyance of some shareholders, Medifast, Inc. ( NYSE:MED ) shares are down a considerable 32% in the last...분석 기사 • May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
Medifast, Inc.'s ( NYSE:MED ) earnings announcement last week didn't impress shareholders. While the headline numbers...분석 기사 • May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Seeking Alpha • Mar 20
Medifast: Cheap Valuation, Uncertain Future
Summary Medifast has had a successful past with continuous growth and strong financial metrics in the health and wellness industry. However, the dynamic nature of the industry raises concerns about the company's future, particularly when considering the recent rise of GLP-1 medications. Investors should consider the implications of industry changes before making a decision on Medifast as an investment. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Medifast Is Getting Attractive
Summary Medifast is experiencing a decline in stock price despite a strong business and consistent cash flow. The company's focus on health and wellness, along with its strategic alliance with LifeMD, positions it for significant upside. Medifast's Optavia solution offers a comprehensive approach to weight loss and has a large addressable market. Shares are a buy with price target of $60. Read the full article on Seeking Alpha분석 기사 • Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Unfortunately for some shareholders, the Medifast, Inc. ( NYSE:MED ) share price has dived 26% in the last thirty days...Seeking Alpha • Jan 20
Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Summary Medifast is a weight loss and wellness program that has experienced a significant decrease in market cap and revenue in 2023. The company's business model relies on recruiting coaches to sell their program and products, which has been successful in generating revenue and dividends for investors. However, there are risks associated with supply disruption, market volatility, reputation, and government regulation that could impact the company's future performance. Read the full article on Seeking Alpha분석 기사 • Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Key Insights Medifast's estimated fair value is US$140 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Nov 24
Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Summary Medifast has strong financials with a healthy cash position and no debt, but its sales have plummeted, and its business model is questionable. MED's efficiency and profitability metrics are impressive, but its high-priced products may deter customers. The decline in sales can be attributed to tough macroeconomic conditions and competition from weight loss drugs, and the future outlook is uncertain. Read the full article on Seeking Alpha분석 기사 • Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Medifast, Inc. ( NYSE:MED ), is not the largest company out there, but it saw significant share price movement during...Seeking Alpha • Nov 09
Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Summary Medifast, Inc. stock is down 80% from its mid-2021 peak, and from a valuation perspective, it looks like a veritable deep-value opportunity. Medifast is currently facing challenges due to elevated consumer price inflation, but increasingly also due to weight loss drugs like Wegovy and soon also Zepbound (or at least their narrative). In this article, I take a look at Medifast's business model, its profitability, and its balance sheet quality against the backdrop of this undoubtedly challenging environment. I also discuss MED's Q3 earnings and whether there is any truth to the theory that GLP-1 receptor agonists pose an existential threat to Medifast's business model. However, I also highlight another potential investment risk that relates to Medifast's most important asset - its coaches. Read the full article on Seeking Alpha주주 수익률
| MED | US Personal Products | US 시장 | |
|---|---|---|---|
| 7D | 0.3% | -2.1% | -0.3% |
| 1Y | -6.1% | -20.0% | 26.7% |
수익률 대 산업: MED은 지난 1년 동안 -20%의 수익을 기록한 US Personal Products 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: MED은 지난 1년 동안 26.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 7.8% |
| Personal Products Industry Average Movement | 7.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: MED는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: MED의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1980 | 380 | Dan Chard | medifastinc.com |
는 자회사를 통해 미국에서 체중 감량을 위한 습관 기반 및 코치 가이드 라이프스타일 솔루션을 제공하는 건강 및 웰니스 회사로 운영되고 있습니다. 이 회사는 체중 감량, 체중 관리 및 건강한 생활을 위한 바, 시리얼, 스낵 스트로우, 핫 초콜릿, 하티 초이스, 오트밀, 팬케이크, 푸딩, 소프트 서브, 쉐이크, 스무디, 소프트 베이크, 수프, 필수 아미노산 혼합물, 유청 단백질, 따뜻한 음료, 브라우니, 미니 식사 등 Essential Fuelings, OPTAVIA ASCEND 및 OPTAVIA ACTIVE 카테고리와 멀티비타민, 미네랄 및 오메가-3 지방산 보충제를 포함한 일일 영양 팩으로 구성된 제품을 제공하고 있습니다. 또한 강력한 목표 지방 연소를 활성화해 신체의 신진대사를 리셋하는 '5 & 1 플랜'과 '5 & 1 액티브 플랜', 모든 식품군을 지속적으로 섭취하거나 건강한 체중 달성을 위해 유연한 식사 계획을 원하는 고객을 위한 '최적 체중 4 & 2 & 1 플랜'과 '최적 체중 4 & 2 액티브 플랜'으로 구성된 라이프스타일 플랜을 제공합니다; 고객의 장기적인 체중 관리를 돕는 맞춤형 접근 방식인 옵타비아 옵티마이제이션 플랜, 고객이 무엇을 먹어야 할지 고민할 필요 없이 체중 감량에 집중할 수 있도록 돕는 GLP-1 약물의 영양 보조제인 옵타비아 GLP-1 뉴트리션 서포트 플랜이 있습니다.
Medifast, Inc. 기초 지표 요약
| MED 기초 통계 | |
|---|---|
| 시가총액 | US$129.19m |
| 순이익 (TTM) | -US$20.02m |
| 매출 (TTM) | US$346.10m |
0.4x
주가매출비율(P/S)-6.5x
주가수익비율(P/E)MED는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| MED 손익계산서 (TTM) | |
|---|---|
| 매출 | US$346.10m |
| 매출원가 | US$103.41m |
| 총이익 | US$242.70m |
| 기타 비용 | US$262.72m |
| 순이익 | -US$20.02m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.95 |
| 총이익률 | 70.12% |
| 순이익률 | -5.79% |
| 부채/자본 비율 | 0% |
MED의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 21:53 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Medifast, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |